EGFR and non-small cell lung carcinoma: Interestingly, a combination of NRI and SIRI was the best model for predicting clinical outcomes in NSCLC patients treated with EGFR-TKI, especially as a prognostic biomarker for predicting both OS and PFS in patients with EGFR exon19Del mutation, EGFR L858R mutation, TNM stage IV, LUAD, and treatment with gefitinib and predicting PFS in patients with young (< 60 y), male, and not receiving surgery treatment.